Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters
Plasma pgRNA declines are modest under NUC therapy, with only 16.3% achieving RNA undetectability after 5 years of first-line NUC indicating cccDNA silencing has not been achieved in the majority of patients. Clinical characteristics should be taken into consideration when interpreting the plasma pgRNA level.
Authors
- Rex Wan‐Hin Hui (ORCID: https://orcid.org/0000-0001-7447-7539)
- Mark G. Anderson (ORCID: https://orcid.org/0000-0002-3231-4296)
- Lung‐Yi Mak (ORCID: https://orcid.org/0000-0002-2266-3935)
- Michael Stec
- Man‐Fung Yuen (ORCID: https://orcid.org/0000-0001-7985-7725)
- Wai‐Kay Seto (ORCID: https://orcid.org/0000-0002-9012-313X)
- Matthew Shing-Hin Chung
- Danny Ka‐Ho Wong
- Gavin Cloherty (ORCID: https://orcid.org/0009-0000-8221-7905)
Institutions
- Queen Mary Hospital (CN)
- Abbott Fund (US)
- University of Hong Kong (HK)
Publication Details
- Journal
- Clinical and Molecular Hepatology
- Published
- 2024-12-26
- DOI
- https://doi.org/10.3350/cmh.2024.0724
- Citations
- 4
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.55